Work

ALL-597: Outcomes in Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Receiving Inotuzumab Ozogamicin Stratified by Body Mass Index

Year: 2025

Type: conference-abstract

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/s2152-2650(25)01541-1

Authors: Wendy Stock, Ryan Cassaday, Daniel J. DeAngelo, Anjali Advani, Nicola Gokbuget, Josep Ribera, Wei Jiang, Susana Pulido, Erik Vandendries, Elias Jabbour, Hagop Kantarjian

Institutions: University of Chicago, University of Washington, Fred Hutch Cancer Center, Dana-Farber Cancer Institute, Cleveland Clinic, University Hospital Frankfurt, Institut Català d'Oncologia, Pfizer (United States), Pfizer (Spain), The University of Texas MD Anderson Cancer Center

Language: English

Topic: Acute Lymphoblastic Leukemia research

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4413791863

Cites:

Cited by:

Related to: 10